Cancer Research In China Research Articles

Hotspots and frontiers in cervical cancer research: A bibliometric and visualization analysis from 2013 to 2022

AbstractBackgroundCervical cancer is a highly aggressive cancer that seriously affects the physical and mental health and quality of life of women, especially for women in developing countries. Therefore, cervical cancer has always been the focus of research, and in recent years, various studies on cervical cancer have emerged one after another.MethodsOur study aimed to illustrate the development trends in cervical cancer research in China from 2013 to 2022 and compare the findings with studies in other parts of the world during the same period by using bibliometric analysis and the Science Citation Index Expanded. Literature data were analyzed and visualized by using CiteSpace and VOSviewer.ResultsThe results show that the number of articles on cervical cancer has increased in recent years, among which articles on the pathogenesis and epidemiological characteristics of cervical cancer account for the majority. The research in China has developed rapidly in recent years, but there is still a certain gap compared with other developed countries.ConclusionBibliometric and visualization analyses offer a unique and objective perspective in the field of cervical cancer and may assist scholars in identifying new research directions.

The landscape of cancer research and cancer care in China.

The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country's cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer.

Challenges and opportunities in rare cancer research in China.

Cancer is one of the major public health challenges in China. Rare cancers collectively account for a considerable proportion of all malignancies. The lack of awareness of rare cancers among healthcare professionals and the general public, the typically complex and delayed diagnosis, and limited access to clinical trials are key challenges. Recent years have witnessed an increase in funding for research related to rare cancers in China. In this review, we provide a comprehensive overview of rare cancers and summarize the status of research on rare cancers in China and overseas, including the trends of funding and publications. We also highlight the challenges and perspectives regarding rare cancers in China.

The past, present, and future of liver cancer research in China

Liver cancer is among the leading causes of cancer-related death worldwide and China accounts for nearly half of the global burden of liver cancer. Effective interventions such as hepatitis vaccinations, new blood tests and imaging tests significantly decreased the incidence worldwide, especially in China. Unraveling the systemic and molecular mechanisms of liver cancer would contribute to develop more effective therapies to prolong the 5 year survival of the patients. The Chinese funding agencies have been paying high attention to the basic and translational research of liver cancer. Over the last decade, the National Natural Science Foundation of China (NSFC) initiated a panel of research programs which supported liver cancer research in multiple directions. Besides, great progress has been made in basic and clinical research, platform construction and drug development in the field of liver cancer. In this article, we summarized the funding landscape, research progress, cooperation among countries and institutions, and drug discovery in China, with an attempt to compare the status and outcome with our peers globally.

Hotspots and prospects of esophageal cancer research in China

Esophageal cancer is a malignant tumor with a high incidence in China. At pesent, advanced esophageal cancer patients are still frequently encountered. The primary treatment for resectable advanced esophageal cancer is surgery-based multimodality therapy, including preoperative neoadjuvant therapy, such as chemotherapy, chemoradiotherapy or chemotherapy plus immunotherapy, followed by radical esophagectomy with thoraco-abdominal two-field or cervico-thoraco-abdominal three-field lymphadenectomy via minimally invasive approach or thoracotomy. In addition, adjuvant chemotherapy, radiotherapy, or chemoradiotherapy, or immunotherapy may also be administered if suggested by postoperative pathological results. Although the treatment outcome of esophageal cancer has improved significantly in China, many clinical issues remain controversial. In this article, we summarize the current hotspots and important issues of esophageal cancer in China, including prevention and early diagnosis, treatment selection for early esophageal cancer, surgical approach selection, lymphadenectomy method, preoperative neoadjuvant therapy, postoperative adjuvant therapy, and nutritional support treatment.

Spatiotemporal Hotspots of Study Areas in Research of Gastric Cancer in China Based on Web-Crawled Literature.

Gastric cancer is a common malignancy worldwide and poses a serious threat to human public health. The difficulty in obtaining epidemiological data limits the development of cross-disciplinary related research. In this study, 99,364 publications on gastric cancer from 1991 to 2019 were obtained using web-crawler technology, and a technical framework for extracting toponyms from these publications was constructed to analyze spatiotemporal hotspots of study areas in gastric cancer research in China. The results showed the following: (1) The accuracy of toponym extraction was greatly improved after eliminating the systematic exclusion words and adding historical toponyms, with a precision of 95.31% and a recall of 94.86%. (2) Gastric cancer research (GCR) and gastric cancer research with toponyms (GCRWT) are attracting increasing amounts of attention. The amount of GCR results published in Chinese and English is gradually leveling off, and the imbalance between those of GCRWT is gradually widening. (3) The spatial distribution of gastric cancer research in China is uneven, and the hotspots are mainly located in the eastern coastal areas. There were huge advances in gastric cancer research at the province/city/county scale in Eastern China, while the central region has only increased research at the county scale. We suggest that gastric cancer research should pay more attention to the central region, which has the highest gastric cancer incidence/mortality. This study provides important clues for research on and investigations of gastric cancer.

Cancer research driven by cutting-edge multi-disciplinary technologies

Cancer is a serious threat to human life and health. It has become the leading cause of death worldwide. According to the National Cancer Center 2019 National Cancer Report, there were about 4 million new cases of cancer in China in 2015, and 8 people were diagnosed with cancer and 5 people died of cancer every minute. Currently, cancer remains a major threat to human health in China and is associated with a high mortality rate. While great efforts have been devoted to the development of cancer therapies, including surgery, radiotherapy, chemotherapy, traditional Chinese medicine, targeted therapy, and immunotherapy, most cancer therapies fail to achieve satisfactory efficacy, which is closely related to the lack of understanding of tumors in modern science, absence of major breakthroughs in the field of cancer research using key cutting-edge technologies, and limited translation and application of the achievements of basic research findings. Cancer represents a collection of multi-origin and multi-step systemic chronic diseases with various outcomes. The high heterogeneity of cancer poses a challenge for traditional therapeutic approaches to treat one type of tumor with the same method but provides opportunities to promote personalized therapies, including immunotherapy and targeted therapy. To promote original and innovative cancer research in China, it is essential to take advantage of modern genetic technology, stem cell technology, molecular imaging technology, molecular diagnosis, bioinformatics, innovative drug development, physical and chemical research methods, and alternative cutting-edge technologies, combined with extensive clinical data and patient population in China. For these reasons, the National Natural Science Foundation of China organized the 223rd Shuangqing Forum titled “Cancer Research Driven by Cutting-edge Multi-disciplinary Technologies”. Forty-five scholars from more than 30 universities and research institutes in China were invited to participate in this forum, and summarized the current status and trend in cancer research, especially the role of cutting-edge technologies in promoting cancer research, the key future research directions, and key scientific challenges. Based on the discussion of forum participants, this review highlights the current status, progress, challenges, and opportunities of cancer research in China, and presents the achievement and importance of multi-disciplinary technologies in driving cancer research and developing cancer therapy and diagnostics. It also summarizes the key scientific questions in the cancer research field for the next 5 to 10 years, and proposes strategies to fund cutting-edge technologies in exploring cancer research in China.

Chinese Cancer Research in 2009-18 and the Disease Burden.

ObjectiveWe investigated the correlation of cancer research in China with its disease burden and national or provincial wealth. We also compared China’s research output with that of other Asian countries.MethodsChinese publications on cancer research for 2009–18 were retrieved from the Web of Science with a special filter giving high precision and recall. Their volume relative to gross domestic product (GDP) was compared with those of 14 Asian countries, and provincial outputs with provincial GDPs. Their distribution by anatomical site was compared with China’s disease burden, and by research type with that of Europe.ResultsChinese cancer research publications (including those from Taiwan) have grown rapidly in the last 10 years, and overtook those of the USA in 2018. Relative to other Asian countries, Chinese output was approximately proportionate to its wealth. Relative to its cancer burden (as a percentage of the total disease burden), China published an appropriate amount of cancer research in 2009–13, but almost one-third more in 2014–18. Its distribution between the provinces reflected their wealth, but with comparatively greater outputs from Beijing and Shanghai. The distribution of China’s cancer research portfolio by anatomical site corresponded to its disease burden quite well, with a heavy emphasis on liver and stomach cancer. However, China did relatively less research on screening, diagnosis, palliative care, or quality of life.ConclusionThe national and provincial cancer research in China in the past 10 years correlated relatively well with its disease burden and economic level, but over-emphasised basic research compared with prevention, screening and end-of-life care.

Extraction of BI-RADS findings from breast ultrasound reports in Chinese using deep learning approaches

BackgroundThe wide adoption of electronic health record systems (EHRs) in hospitals in China has made large amounts of data available for clinical research including breast cancer. Unfortunately, much of detailed clinical information is embedded in clinical narratives e.g., breast radiology reports. The American College of Radiology (ACR) has developed a Breast Imaging Reporting and Data System (BI-RADS) to standardize the clinical findings from breast radiology reports. ObjectivesThis study aims to develop natural language processing (NLP) methods to extract BI-RADS findings from breast ultrasound reports in Chinese, thus to support clinical operation and breast cancer research in China. MethodsWe developed and compared three different types of NLP approaches, including a rule-based method, a traditional machine learning-based method using the Conditional Random Fields (CRF) algorithm, and deep learning-based approaches, to extract all BI-RADS finding categories from breast ultrasound reports in Chinese. ResultsUsing a manually annotated dataset containing 540 reports, our evaluation shows that the deep learning-based method achieved the best F1-score of 0.904, when compared with rule-based and CRF-based approaches (0.848 and 0.881 respectively). ConclusionsThis is the first study that applies deep learning technologies to BI-RADS findings extraction in Chinese breast ultrasound reports, demonstrating its potential on enabling international collaborations on breast cancer research.

Yinghao Sun: leader of research on prostate cancer in China

Yinghao Sun: leader of research on prostate cancer in China

The past, present and future of breast cancer research in China

The incidence of breast cancer has increased rapidly in recent years and has now become the most common cancer in women in major cities of China. Here, we reviewed the history and progress of breast cancer research in China, including achievements that Chinese scientists have made in basic, translational and clinical research. Moreover, we evaluated the contributions of National Natural Science Foundation of China (NSFC) in the field of breast cancer research. The number of grants funded by the NSFC for breast cancer has tripled from 87 to 274 in the past 5years, and this resulted in a dramatic increase in breast cancer publications. Despite this great progress, policy makers are continuously taking efforts to guarantee the transparency of grant competition and the effective use of NSFC finding.

Prostate cancer research in China

Prostate cancer (PCa) research in China has been on a rocketing trend in recent years. The first genome-wide association study (GWAS) in China identified two new PCa risk associated single nucleotide polymorphisms (SNPs). Next generation sequencing is beginning to be used, yielding novel findings: gene fusions, long non-coding RNAs and other variations. Mechanisms of PCa progression have been illustrated while various diagnosis biomarkers have been investigated extensively. Personalized therapy based on genetic factors, nano-medicine and traditional Chinese medicine has been the focus of experimental therapeutic research for PCa. This review intends to shed light upon the recent progress in PCa research in China and points out the possible breakthroughs in the future.

Achievements in cancer research supported by National Natural Science Foundation of China

For the past two decades, great achievements have been made in cancer research of China and the majority of them were supported by the National Natural Science Foundation of China (NSFC). In this article, we reviewed the funding history of NSFC including the number of proposals, the amount of grants, distribution of supported program categories during the period of 1987 to 2012 and the representative achievements made by continuous support of NSFC. Also, the impacts of NSFC support on discipline development and talent fostering were analyzed. From 1987 to 2012, a total of 8738 proposals related to cancer research were funded by NSFC. The percentages of the Research Program, Talent-Training Program, and the Research Environment Program were 61.19%, 36.32%, and 2.49%, respectively. Under the support of NSFC, cancer research in China has achieved a significantly rapid and balanced development in both disciplines and scientist resources.

Bridging the US and China together to conquer cancer: report of the 4th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA)

A global collaborative effort is pivotal to conquer cancer. Themed “Emerging role of China in global clinical development of novel anti-cancer drugs”, the US Chinese Anti-Cancer Association (USCACA) held its 4th annual meeting in Chicago on June 2, 2012, in conjunction with the American Society of Clinical Oncology (ASCO) annual meeting to further bridge the US and China together to outsmart cancer. Although a young organization, USCACA has made significant contributions to this goal in the 3 years since its inception through extensive collaboration with academic organizations, the pharmaceutical industry, and governmental agencies. USCACA has engaged various stakeholders in developing translational and personalized medical strategies to facilitate new anti-cancer drug development and clinical trials in China. USCACA has initiated and implemented the USCACA-National Foundation for Cancer Research (NFCR) scholarship to encourage overseas returnees to continue cancer research in China. USCACA announced the Hengrui-USCACA scholarship to fund clinical trial staff from China to conduct the observation of early oncologic clinical trials in the US. During the annual meeting, distinguished panelists and the audience discussed the following critical topics: (1) oncologic translational research and early development capabilities in China; (2) novel chemical entity development and partnership with Chinese companies; and (3) Chinese participation in global anti-cancer drug development. USCACA will continue to promote collaborations among cancer researchers and clinicians in the US and China by engaging in more frequent communications and joint efforts across fields, disciplines, and countries, diligently working together toward curing and eliminating cancers.

Cancer research in China: a Special Focus by Cell Research

Cancer research in China: a Special Focus by Cell Research

A thing and prospecting of gastric cancer research in China

在我国,胃癌与其他常见肿瘤一样发病率居高不下,现有的诊疗方法不宜早期发现,难以获得满意的疗效.以往的临床资料表明,早期胃癌术后的5年生存率明显高于中晚期,特别是日本早期胃癌诊断率远远高于我国,但是,针对我国现有的经济实力和医学知识与技术的普及程度,我们在短时间不可能采用同样的方式去实现这样的目标.为此,应结合我国所面临的胃癌防治的科学问题、社会需求和我们的实际能力,认真考虑我国胃癌基础和临床的研究策略及模式,为降低发病率、提高早期诊断水平及改善临床疗效,避免治疗不当和过度治疗提供理论指导。

General Information and Statistics

Inject IT to Boost the Biomedical Industry. China and Thailand to Co-produce Acupuncture Needles. Shenzhen to Build Eco-Agricultural High-Tech Park. NZ Authorities Decline Clinical Trials Transplanting Pig Cells to Humans. Kumho Science International Award in Plant Molecular Biology and Biotechnology Presented to Eight Plant Scientists. US Cancer Conference to Focus on Nutrition, Cancer Research in China and Individualization of Cancer Treatments in the 21st Century. Swedish Delegation Seeks Collaboration with Taiwan in Biotech. Singapore Genomics Program Renamed the Genome Institute of Singapore.

Cancer Research in the Far East

WITH the recognition of the widespread incidence of cancer, research into its occurrence, cause and treatment is being pursued in an increasing number of centres. This research is supported by governments, by industry and by private subscription. The biggest effort is undoubtedly being made in the United States of America where very large sums of money are being spent, particularly in the field of chemotherapy of cancer; this is financed mainly by the government United States Health Service and the American Cancer Society which relies on private donations. One had the impression that the support of cancer research in Japan was to some extent dependent on industry. Cancer research in China is necessarily entirely under government support and control, but some of the buildings used for the research in Chinese cities were originally provided by western benefactions.